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Background: It remains unknown whether current disease-targeting therapy can histologically 
reverse obstructive pulmonary vasculopathy and how the timing of the therapy influences the 
antiremodeling effects of the compound. Objective: We test the hypothesis that a novel 
endothelin receptor antagonist macitentan reverses the early and/or late stages of occlusive 
pulmonary vascular disease (PVD) in rats.  
Methods: Rats with pulmonary arterial hypertension (PAH), which were produced by 
combined exposure to a vascular endothelial growth factor receptor inhibitor Sugen 5416 and 
hypobaric hypoxia for 3 wk, were assigned to receive macitentan or vehicle during 3–5 wk 
(early study) or during 5–8 wk (late study) after Sugen injection.  
Results: Compared with vehicle-treated PAH rats and PAH rats evaluated before treatment 
initiation, the macitentan-treated rats showed decreases in the proportion of occlusive lesions in 
the early study, a finding consistent with the reversal of right ventricular systolic pressure and 
indexes of right ventricular hypertrophy and medial wall thickness. Macitentan ameliorated but 
did not reverse the proportion of occlusive lesions in the late study. Although macitentan 
decreased the proportion of Ki67+ lesions in both studies, macitentan increased the proportion 
of cleaved caspase 3+ lesions and suppressed an antiapoptotic molecule survivin expression in 
the early study but not in the late study. 
Conclusion: macitentan reversed early but not late obstructive PVD in rats. This reversal was 
associated with the suppression of survivin-related resistance to apoptosis and proliferation of 
cells in PVD. 
